# Rhodiola Rosea for Coronary Microvascular Disease

> **NCT04218916** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Qilu Hospital of Shandong University** · enrollment: 114 (estimated)

## Conditions studied

- Coronary Microvascular Disease

## Interventions

- **DRUG:** Rhodiola Rosea Capsules
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04218916
- **Lead sponsor:** Qilu Hospital of Shandong University
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-01
- **Primary completion:** 2021-01
- **Final completion:** 2023-01
- **Target enrollment:** 114 (ESTIMATED)
- **Last updated:** 2020-01-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04218916

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04218916, "Rhodiola Rosea for Coronary Microvascular Disease". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04218916. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*